[Autoimmune autonomic ganglionopathy]

Area of Science:

• Neuroimmunology
• Autonomic Nervous System Disorders
• Diagnostic Assay Development

Context:

• Autoimmune autonomic ganglionopathy (AAG) is characterized by severe autonomic dysfunction due to antibodies targeting ganglionic nicotinic acetylcholine receptors (gAChR).
• Accurate detection of gAChR autoantibodies is crucial for diagnosing AAG and understanding its pathogenesis.
• Current diagnostic methods may require refinement for sensitivity and ease of use.

Purpose:

• To develop and validate a novel, sensitive, non-radioisotopic in vitro assay, GLIP (gaussia luciferase-reporter immunoprecipitation), for detecting antibodies against gAChR.
• To investigate the clinical presentation and treatment response in patients with gAChR autoantibodies and autonomic dysfunction.
• To explore the potential reversibility of autoimmune-mediated autonomic impairment.

Summary:

• A novel GLIP assay was developed to detect antibodies targeting the nicotinic acetylcholine receptor of autonomic ganglia (gAChR).
• Seven patients with gAChR autoantibodies and autonomic dysfunction were identified and evaluated.
• Six of seven patients showed clinical improvement following immunotherapy, correlating with decreased anti-gAChR antibody levels, suggesting partial reversibility of autonomic dysfunction.

Impact:

• The GLIP assay provides a sensitive tool for diagnosing AAG and related autoimmune autonomic neuropathies.
• Findings suggest that autoimmune autonomic dysfunction associated with gAChR antibodies may be partially reversible with immunotherapy.
• This research aids in understanding AAG pathogenesis and optimizing treatment strategies for patients with autonomic failure.